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Response to ‘Re. Beneﬁts of Remote Ischemic
Preconditioning in Vascular Surgery’
The authors make a good point: discrepancy between ani-
mal and clinical data is multifactorial, and the factors they
cite are likely to be an inﬂuence.
Themost recent, properly powered randomised controlled
trial (RCT) of remote ischaemic preconditioning (RIPC) in
cardiac surgery avoided the use of volatile anaesthetic agents
to avoid pharmacological preconditioning.1 This trial showed
no difference between the RIPC and no RIPC groups.
Conversely, the large RIPCON (Remote Ischemic Pre-
Conditioning) trial of RIPC in cardiac surgery is currently
recruiting using volatile agents to avoid remifentanyl,2 which
is also associated with pharmacological preconditioning.3
This highlights one of the problems with medications and
RIPC: it might be impossible to avoid those that effect RIPC
completely, but trials can adjust for the least powerful.
Additionally, patients might fare worse with the pre-
conditioning effect of RIPC than they would have done with
the preconditioning effect of the medication being withheld.
Another problem is that the mechanisms of interference are
still poorly understood, and it is likely that additional,
commonly prescribed medicines have an effect on RIPC.3,4
Other factors such as diabetes are common in vascular pa-
tients should be corrected for if trials are properly powered.
Protocols for other trials currently or about to recruit are
heterogeneous in their approach to correcting for these
factors. To date, 102 trials of remote ischaemic pre-
conditioning are registered on ClinicalTrials.gov. It is
imperative that trialists recognise and attempt to correct for
these factors as early as possible. Without this, we risk
publishing large, ﬂawed trials that essentially destroy all
interest in RIPC without a rigorous method.
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Thrombolysis in Carotid-Related Stroke Patients: What
About Plaque Hemorrhage and Disruption?
The routine practice of thrombolysis in ischemic stroke pa-
tients is derived from well-conducted, randomized controlled
trials (RCTs),1 which are the foundation of evidence-based
medicine (EBM). Those studies have proved themselves
extremely useful for stroke patients, helping somanypeople to
have better outcomes after their strokes. Currently, intrave-
nous thrombolytic therapy is recommended within 4.5 hours
of the onset of symptoms in patients with acute ischemic
stroke, once intracranial bleeding has been excluded by
computed tomography.2,3 The exact identiﬁcation of the site
of occlusion causing the ischemia or, more in general, of the
exact cause of stroke, is not considered mandatory before
starting ﬁbrinolytic therapy, as none of the RCTs studying the
effect of rt-PA in ischemic stroke patients was designed to
address the differential effects on different types or causes of
ischemic strokes by using vascular imaging.4,5 Hence, a carotid
axis scan is not routinely performed until the rt-PA adminis-
tration has been completed. Unfortunately, it is likely that not
all the patients receiving intravenous systemic rt-PA will gain
the greatest efﬁcacy and beneﬁt from ﬁbrinolytic therapy, and
this is probably related to the lack of a careful diagnosis of the
stroke etiology.6 In their capacity as stroke-treating physicians,
vascular surgeons sometimes ﬁnd themselves in the awkward
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position of regretting the injudicious administration of
thrombolysis without making a careful diagnosis of the stroke
etiology and an evaluation of all possible risks and beneﬁts of
thrombolysis against the potential beneﬁt of urgent/emer-
gency endarterectomy.
Here a case of misdiagnosed carotid artery stenosis
causing recurrent ischemic strokes despite e and also
because of e thrombolysis is reported. A 58-year-old
woman was admitted to the authors’ institution with a left
hemispheric stroke within 3 hours of symptom onset.
Hemorrhage was excluded by noncontrast brain CT, and, as
she presented no contraindication, intravenous rt-PA
administration was started. In the following hours her
neurological deﬁcit worsened, shifting from a NIHSS score
of 4 to 9. Brain DW-MRI showed multiple acute left hemi-
spheric ischemic lesions, and carotid duplex ultrasound
showed a hemorrhagic and ulcerated, eroded, and dis-
rupted left carotid plaque causing a 50% stenosis. According
to recall by her relatives, she had had a duplex US scan 9
months previously, demonstrating an irregular, hypoechoic
carotid plaque causing a 60% stenosis in the left carotid
artery with no referred neurological symptoms. She was
then scanned for other potential sources of embolism but
the ﬁnal diagnosis was recurrent brain ischemia caused by
carotid plaque embolism. The patient was then submitted
to delayed carotid endarterectomy.
In the present case prompt diagnosis of plaque hemor-
rhage and disruption as causing neurological symptoms
could have been beneﬁcial in planning the best multidisci-
plinary strategy. This is an example where routine practice
according to solid RCTs might, if applied without taking into
account the possibility of recurrent embolization from a
thrombolytic-enhanced disrupted carotid plaque, become
harmful rather than curative.
There is growing evidence that management of ischemic
stroke patients ismore andmore amultidisciplinary approach.
The possibility of performing urgent e or even emergency e
carotid US should be taken into account in stroke manage-
ment, considering that it will take just a few minutes in
experienced hands, so that it is also possible to perform it
during thrombolytic drug administration. It surely implies that
emergency services should be reorganized, but the ultimate
beneﬁt would be that stroke patientswould have all the stroke
specialists promptly working for them. In the case of carotid
plaque disruption, emergency carotid endarterectomy might
be considered, and careful evaluation of risks and beneﬁt
should be made only once all the aspects of vascular
involvement have been evaluated by accurate imaging. In
properly selected patients, urgent endarterectomy, allowing
heparin administration and internal carotid artery backﬂow to
enhance the possibility of clearing the distal internal carotid
artery together with careful plaque excision, could prove
extremely beneﬁcial. Vascular surgeons should become more
involved in stroke treatment, even if it means rearranging
stroke management services and being “on call” for urgent/
emergency carotid revascularization 7 days a week.
The authors wonder if anyone else has had a similar
experience and would be very interested in hearing opinion
on the advisability of thorough vascular imaging to identify
the cause of stroke before starting any treatment in
ischemic stroke patients.
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Re. ‘Identiﬁcation of Patients with a Histologically
Unstable Carotid Plaque Using Ultrasonic Plaque Image
Analysis’
We read with interest the paper by Salem et al.1 The
authors investigated ultrasound imaging as a potential
method for the identiﬁcation of vulnerable stenotic carotid
artery plaques.1 Because reliable markers of vulnerability
are still lacking, ultrasound imaging could be a feasible
method for risk stratiﬁcation.
The authors histologically analysed 126 carotid plaque
specimens (104 symptomatic; 22 asymptomatic) with re-
gard to several well established histological features. Ul-
trasound data were compared with the pathological ﬁnding
of ‘stable/unstable’ plaque based on the subjective evalu-
ation of two blinded pathologists. Of note, this classiﬁcation
did not lead to a distinction between symptomatic and
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